Related Experiment Video

Updated: Jun 26, 2026

Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection
06:11

Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection

Published on: May 17, 2024

The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective

M Kaplan1, C Hammerman

  • 1Department of Neonatology, Shaare Zedek Medical Center, Jerusalem, Israel. kaplan@cc.huji.ac.il

Journal of Perinatology : Official Journal of the California Perinatal Association
|January 30, 2009
PubMed

Insights

Global screening for Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency in newborns is crucial. Early detection before hospital discharge improves awareness and timely treatment for neonatal hyperbilirubinemia and kernicterus.

Area of Science:

  • Biochemistry
  • Genetics
  • Neonatology

Background:

  • Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is a significant cause of severe neonatal hyperbilirubinemia.
  • This deficiency is disproportionately linked to kernicterus, even in regions with low overall incidence.

Observation:

  • Neonatal screening for G-6-PD deficiency before hospital discharge can enhance awareness among parents and caregivers.
  • This increased awareness facilitates earlier medical evaluation and treatment for affected infants.

Findings:

  • Participants at the Newborn Jaundice and Kernicterus Meeting agreed on the necessity of expanding global neonatal G-6-PD screening.
  • Screening results must be available before infant discharge from the birth hospitalization.

Implications:

  • Implementing universal neonatal G-6-PD screening can reduce the incidence of severe hyperbilirubinemia and kernicterus.
  • The discussion highlighted the need to consider the optimal timing and methods (biochemical vs. molecular DNA) for screening.

More Related Videos

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure09:28

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

Biochemical Measurement of Neonatal Hypoxia13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...